Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets

Journal of Clinical Pharmacology

Volumn 45, Issue 7, 2005, Pages 802-809

  Abdallah, Hisham ^a   Jerling, Markus ^a,b  

^a CV THERAPEUTICS INC   (United States)

^b NONE   (Sweden)

Author keywords

Hepatic impairment; Pharmacokinetics; Ranolazine

Indexed keywords

CVT 2512; CVT 2514; CVT 2738; DRUG METABOLITE; MIDAZOLAM; RANOLAZINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LIVER DISEASE; LIVER FUNCTION; MALE; MULTIPLE DRUG DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA HALF LIFE; QT PROLONGATION; SUSTAINED RELEASE FORMULATION;

AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DELAYED-ACTION PREPARATIONS; ENZYME INHIBITORS; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDAZOLAM; MIDDLE AGED; PIPERAZINES; TABLETS;

EID: 21044458297     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005276739     Document Type: Article

References (9)

1. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris subjects treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20:131-138.
2. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in subjects with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316.
3. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in subjects with severe coronary artery disease and chronic angina: the MARISA trial. J Am Coll Cardiol. 2004;43:1375-1382.
4. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol. 1999;84:46-50.
5. 14C]- ranolazine in humans [abstract 98], Drug Metab Rev. 2003;35(suppl 2):49.
6. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
7. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Subjects With Impaired Hepatic Function-Study Design, Data Analysis, and Impact on Dosing and Labeling. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Available at: http://www.fda.gov/cder/guidance/3625fnl.pdf.
8. Morgan DI, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in subjects with liver disease: an update. Clin Pharmacokinet. 1995;29:370-391.
9. Chu N, Soohoo D, Sun H-L, et al. In vitro metabolism of ranolazine [abstract 363]. Drug Metab Rev. 2003;35(suppl 2):182.